Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes

Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes

Accepted version

Peer-reviewed

Repository URI

https://www.repository.cam.ac.uk/handle/1810/265908

Repository DOI

https://doi.org/10.17863/CAM.12276

Files

Published version (145.86 KB)

Type

Authors

Williams, Edward

https://orcid.org/0000-0001-9187-2258

Keywords

Cancer immunotherapy, T cell checkpoint inhibitor, clinical trial, glucocorticoid, immunomodulation, immunosuppression

Journal Title

Annals of Oncology

Journal ISSN

0923-7534
1569-8041

Volume Title

28

Publisher

Oxford University Press

Publisher DOI

https://doi.org/10.1093/annonc/mdx181

Rights and licensing

Attribution 4.0 International

Except where otherwised noted, this item's license is described as Attribution 4.0 International

Sponsorship

Cancer Research UK (15678)

This work was supported by the Wellcome Trust Translational Medicine and Therapeutics Programme [RJAG/076 to TJ], Cancer Research UK and the Cambridge Translational Medicine and Therapeutics Academic Clinical Fellowship Programme (to CMC).

Collections

Scholarly Works - Oncology